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We examined association of inducible myocardial perfusion defects with cardiorenal biomarkers, and of diminished left
ventricularejectionfraction(LVEF)withkidneyinjurymarkerplasmaneutrophilgelatinase-associatedlipocalin(NGAL).Patients
undergoing nuclear myocardial perfusion stress imaging were divided into 2 groups. Biomarkers were analyzed pre- and poststress
testing. Compared to the patients in the low ischemia group (n = 16), the patients in the high ischemia group (n = 18)
demonstrated a signiﬁcantly greater rise in cardiac biomarkers plasma BNP, NT-proBNP and cTnI. Subjects were also categorized
based on pre- or poststress test detectable plasma NGAL. With stress, the group with no detectable NGAL had a segmental defect
score4.2comparedto8.2(P = .06)inthedetectableNGALgroup,and0.9vs.3.8(P = .03)atrest.BNProsewithstresstoagreater
degree in patients with detectable NGAL (10.2 vs. 3.5pg/mL, P = .03). LVEF at rest and with stress was signiﬁcantly lower in the
detectable NGAL group; 55.8 versus 65.0 (P = .03) and 55.1 vs. 63.8 (P = .04), respectively. Myocardial perfusion defects associate
with biomarkers of cardiac stress, and detectable plasma NGAL with signiﬁcantly lower LVEF, suggesting a speciﬁc heart-kidney
link.
1.Introduction
Bidirectional signaling between the heart and the kidneys
is being increasingly recognized as an important determi-
nant of progression of disease states in both organs. This
interorgan relationship, called the cardiorenal syndromes,
has been deﬁned with a novel classiﬁcation [1] and described
in detail at a recent consensus conference [2]. The accurate
characterization of the types of signaling and their conse-
quences is paramount to the understanding of cardiorenal
and renocardiac syndromes [1].
Both in coronary artery disease (CAD) and congestive
heart failure (CHF) the levels of plasma B-type natriuretic
peptides(BNPs)havebeenshowntobeelevatedcomparedto
healthy controls [3, 4]. Furthermore, BNPs have established
their role in diagnosing acute heart failure [5, 6]a n dh a v e
been shown to be strong prognostic markers for mortality
in CAD [7, 8] and CHF patients [9], with and without renal
insuﬃciency [10–13].
Neutrophil gelatinase-associated lipocalin (NGAL) is a
novelbiomarkerreﬂectingdamagetorenaltubularcells,with
elevated levels in urine and plasma from two hours onwards
after acute insult to the kidneys [14]. Moreover, the rise
of NGAL is detectable substantially faster than the possible
rise in plasma creatinine thus allowing diagnosis of acute
kidney injury earlier, and with better sensitivity [15]. NGAL2 International Journal of Nephrology
has been shown to be elevated also in patients with CHF,
suggesting an association between cardiac and renal damage
[16, 17].
During cardiac stress testing, a number of studies have
indicated that BNPs may be higher at baseline or increase to
a greater extent in those whose tests indicated the presence
of ischemia [18, 19]. No published data exist on whether
inducible myocardial ischemia during cardiac stress testing
can cause injurious signaling to the kidneys measured by
increase in plasma NGAL.
We designed this study in patients undergoing nuclear
myocardial perfusion stress imaging to examine the rela-
tionship between baseline and poststress changes in the
number of myocardial perfusion defects (as a surrogate for
cardiac ischemia), with levels of several cardiac biomarkers
(BNP, N-terminal-proBNP and cardiac troponin I), markers
of oxidative stress (advanced oxidation protein products),
pre- and poststress cardiac chamber size and left ventric-
ular ejection fraction (LVEF). We also examined for an
association between cardiac ischemia and diminished LVEF,
and kidney injury through measurement of the biomarker
plasma NGAL.
We hypothesized that subjects demonstrating higher lev-
els of perfusion defects would have increased poststress levels
of cardiac biomarkers, altered cardiac chamber dimensions,
lower LVEF and increased levels of plasma NGAL.
2. Patientsand Methods
2.1. Patients and Study Protocol. The study was performed
and the blood samples collected and analyzed in San
Bortolo Hospital, Vicenza, Italy, between December 2007
and February 2008. Consecutive adult patients undergoing
elective nuclear stress perfusion imaging fulﬁlling inclusion
criteriawereinvitedtoparticipate.Anyoutpatientplannedto
go to perfusion test was eligible for participation, regardless
of the indication for the test, with the exclusion of patients
with prior heart or kidney transplant. A convenience sample
of 34 patients consented to the study. Nuclear stress test
was performed according to hospital’s normal procedure,
and informed consent was obtained from all patients who
participated in the study. The study was approved by the
Institutional Review Board.
Subjects underwent perfusion stress imaging performed
on a Tuesday of the week of enrollment, and blood samples
were drawn approximately 10 minutes before, and two hours
after the stress test, prior to discharge from the Nuclear
Medicine department. A subsequent imaging study at rest
was performed on the Friday of the same week to provide
baseline perfusion images, during which no additional blood
was drawn. The stress test was performed using bicycle
ergometer exercise (16 patients), or pharmacologically using
dipyridamole (0.56mg/kg intravenously in 4 minutes) fol-
lowed by aminophylline 120mg intravenously (240mg if
any symptoms of side eﬀects of dipyridamole were present).
The scintigraphy was performed according to EANM/ESC
guidelines [20], using 99mTc-sestamibi as tracer and a two-
day gated SPECT protocol. The perfusion scan results were
interpreted by two experts as per standardized guidelines for
reporting [21, 22], blinded to the experimental laboratory
results.
The recorded variables included date of birth, sex,
age, type of perfusion study and stress (i.e., exercise or
pharmacologic), cardiac risk factors, and previous known
myocardial infarction or coronary artery disease. Medi-
cations that may inﬂuence BNP were recorded (nitrates,
calcium antagonists, and beta blockers). The adequacy of
the stress test was assessed by peak heart rate and blood
pressure. Segmental myocardial perfusion defects at rest and
with stress were reported per standardized guidelines as well
as cardiac left ventricular end diastolic volume, end systolic
volume, and ejection fraction. Changes with stress were
calculated for all relevant variables. Ejection fraction and
related measurements were compared between the rest and
stress study results to calculate the changes (deltas).
Plasma creatinine was measured at baseline to determine
the presence or absence of kidney dysfunction. Blood sam-
ples were taken pre- and postperfusion testing and analyzed
for blood hemoglobin, plasma albumin, creatinine, BNP, N-
terminal-proBNP (NT-proBNP), cardiac troponin I (cTnI),
NGAL, and advanced oxidation protein products (AOPP).
Changes in hematocrit and albumin with stress indicated
acuteshiftsinplasmavolumeaspreviouslydescribedin[23],
hence poststress values for all relevant analytes were adjusted
based on delta albumin.
2.2. Speciﬁc Laboratory Techniques. Plasma BNP and cTnI
were analyzed using immunochemiluminescence immuno-
assay and ADVIA Centaur analyzer (Siemens Healthcare
Diagnostics Inc., Deerﬁeld, IL) and plasma NT-proBNP
with electrochemiluminescence immunoassay and Elecsys
2010 analyzer (Roche Diagnostics AG, Rotkreuz, Switzer-
land). Plasma samples for NGAL were quickly stored in
minus 80 degrees Celcius for later analysis. Plasma NGAL
was measured with ﬂuorescence-based immunoassay with
the Triage point-of-care analyzer (Biosite Inc., San Diego,
CA, USA), which is a rapid quantitative measurement of
NGAL concentration in EDTA-anticoagulated whole blood
or plasma (single-use plastic cartridges with immobilized
NGAL antigen and containing NGAL-speciﬁc monoclonal
antibodies conjugated to ﬂuorescent nanoparticles). The
detection limits for this NGAL analysis are 60–1300ng/mL.
AOPP were measured by spectrophotometry and concentra-
tions were expressed as micromoles per liter of chloramine-T
equivalents.
2.3. Statistical Methods. According to the median value
for inducible perfusion defects, which deﬁned two groups
(low and high inducible ischemia), study parameters were
compared between-groups using unpaired t-tests (Mann-
Whitney U test for skewed variables) or Fisher’s exact test
for categorical variables. Within-group changes (pre- and
poststress) were analyzed using paired t-tests (or Wilcoxon
signed rank test). Many NGAL levels were below the level
of detection, and accurate pre- and postdeltas could not be
calculated, hence comparisons could not be made between
the low and high inducible ischemia groups. Therefore,
subjects were categorized based on any level of detectableInternational Journal of Nephrology 3
NGAL(≥60ng/mL)eitherbeforeorafterstressimaging,and
the study parameters (cardiac biomarkers, cardiac chamber
sizes, segmental defect scores) were compared between those
with (n = 23) and without (n = 11) evidence of detectable
NGAL. Analyses were conducted using SPSS version 16.0
(SPSS Inc., Chicago, Illinois) and P<. 05 was required for
statistical signiﬁcance. Unless otherwise speciﬁed, values are
expressed as mean ± standard deviation.
3. Results
There were 16 and 18 subjects in the low and high inducible
ischemia groups, respectively. The groups were similar for
all baseline demographic, laboratory, and cardiovascular
parameters, with the exception of prior history of coro-
nary angioplasty, which was more prevalent in the high
inducible ischemia group (Table 1). Plasma albumin and
hemoglobin fell signiﬁcantly two hours after stress testing
(P<. 001).
Changes in cardiac biomarkers, oxidative stress, and var-
ious cardiovascular imaging parameters compared between
the high and low inducible ischemia groups are presented in
Table 2. Patients in the high ischemia group demonstrated a
consistent rise in cardiac biomarkers with stress. For exam-
ple, the rise in BNP following stress was 8.0pg/mL greater in
the high ischemia than the low ischemia group (delta-BNP
11.8pg/mL versus 3.8pg/mL, 95% conﬁdence interval 1.2–
14.7; P = .02). A similar pattern was seen with NT-proBNP,
which increased more in the high ischemia group compared
to the low ischemia group (delta NT-proBNP 59.1pg/mL
versus 5.0pg/mL, 95% conﬁdence interval 4.9–103.3; P =
.03). Likewise, the poststress cTnI rose to 0.016µg/L in the
high ischemia group and to 0.008µg/L in the low ischemia
group (P = .05). A trend was seen with respect to change in
end-diastolic volume, which increased in the high ischemia
group by 6.5mL versus 0.1mL in the low ischemia group
(P = .07). There also was a weaker trend towards higher
oxidative stress in the high ischemia group, with AOPP of
121.2µmol/L in the high ischemia versus 77.0µmol/L in the
low ischemia group (P = .15).
Plasma NGAL levels were below the limits of detection
in many instances, both before and after stress, hence pre-
and postcomparisons could not be made between groups
basedontheirlevelofinducibleischemia.However,whenthe
subjects were divided into two groups based on the presence
o ra b s e n c eo fd e t e c t a b l eN G A Ll e v e l s( ≥60ng/mL), before
or after stress imaging, some clear diﬀerences emerged as
presented in Table 3. Both plasma BNP and NT-proBNP
rose with stress to a greater degree in the detectable NGAL
group,andthiswasstatisticallysigniﬁcantintheformercase,
with BNP rising by 6.7pg/mL more in the NGAL group
(95% conﬁdence interval 1.0–14.4 pg/mL; P = .03). Levels
of cTnI at baseline, prior to stress imaging, were higher
in the detectable NGAL group, at 0.010 versus 0.006µg/L
(P = .05). The subjects with detectable NGAL also had a
signiﬁcantly higher segmental defect score at rest, and higher
end-diastolicandend-systolicvolumesatrestandwithstress.
Ejectionfractionwassigniﬁcantlylowerbothatrestandwith
stress in patients with detectable NGAL (all P<. 05, Table 2).
4. Discussion
We designed this study to examine for evidence of cardiore-
nal signaling in patients with varying degrees of inducible
cardiacischemiaanddiminishedsystolicfunction.Weclearly
identiﬁedthatthosesubjectswithhigherdegreesofinducible
ischemia had a consistent increase in a biomarker of cardiac
injury (cTnI) and biomarkers of cardiac distress (BNP and
NT-proBNP). Furthermore, the patients with lower LVEF
had detectable plasma NGAL, that is, an increase in a
biomarker of kidney injury.
Biomarkers are biological substances of human physiol-
ogy, reﬂecting change in function or appearance of injury
in certain organ or system of organs. The ideal biomarker
is easily measured, speciﬁc for the organ under inspection,
appears early after injury, shows the amount of injury,
and correlates with prognosis [24]. In the discipline of
cardiology, the cardiac troponins have been shown to possess
these properties. In nephrology, early biomarkers indicating
kidney injury have long been longed for and have only
recently become available for clinical use [25].
In addition to cardiac troponins, B-type natriuretic
peptides have gained success as diagnostic and prognostic
biomarkers, especially among CHF patients [26]. BNPs are
secreted by the cardiac ventricles in response to excessive
stretching of myocytes, in heart failure and volume overload,
and ischemic injury to myocardium [27]. Importantly, in
earlier studies elevated levels of BNPs have been shown to
be independent predictors of cardiovascular morbidity and
mortality, both in patients with normal and impaired renal
function, thus emphasizing the value of BNPs in assessment
of cardiorenal syndrome [1, 10]. In our study, the levels
of both BNP and NT-proBNP were signiﬁcantly higher in
patients with more myocardial ischemic perfusion defects.
Neutrophil gelatinase-associated lipocalin (NGAL) has
emerged as a novel biomarker of acute kidney injury (AKI)
[15]. NGAL is a 25-kDa protein widely spread within human
body (kidney, prostate, uterus, salivary gland, epithelia of
respiratory, and alimentary tracts) and shown to possess
various biological properties, for instance kidney-protecting
and nephron-inducing activity and bacteriostatic capability
[15]. Although normally expressed at very low levels, it
has been shown to rise in AKI, in human kidney cortical
tubules, urine, and plasma and has therefore become a novel
biomarker of acute renal damage [28]. Furthermore, the
rise of NGAL takes place faster than a possible increase in
plasma creatinine allowing detection of AKI earlier than
with creatinine-based criteria and with good sensitivity and
excellent speciﬁcity [29]. NGAL has been shown to increase
in various settings of cardiac procedures and in critically
ill patients with sepsis, renal ischemia and contrast media-
induced nephropathy [30]. The acute rise of NGAL in most
reported studies has taken place during two to six hours after
an event compromising renal function and causing renal
damage [15].
Interestingly, NGAL has been shown to be elevated in
patients with CHF, possibly demonstrating a link between
cardiac dysfunction and renal injury [16, 17]. This is in line
with the results of our study, in which the patients with4 International Journal of Nephrology
Table 1: Baseline demographic, laboratory, and cardiovascular parameters according to the amount of myocardial ischemia (number of
inducible myocardial perfusion defects).
Baseline variable High inducible ischemia (n = 18) Low inducible ischemia (n = 16) P value
Demographic
Age (years) 70.4 ±6.76 7 .6 ±7.5. 2 5
Sex (% male) 77.87 5 .0. 8 5
Weight (kg) 80.5 ±12.17 8 .1 ±8.0. 6 6
Past history (%)
Hypertension 38.94 3 .8. 7 7
Current smoking 0.01 8 .8. 0 9
Dyslipidemia 66.75 6 .3. 5 3
Diabetes mellitus 22.21 2 .5. 4 6
Myocardial infarction 77.84 3 .8. 0 8
Coronary angioplasty 88.95 0 .0 .02
Coronary bypass graft 5.61 2 .5. 4 8
Medications (%)
Nitrates 16.71 8 .8. 8 7
Calcium antagonists 33.31 2 .5. 2 3
Beta blockers 27.8 31.3 .82
Laboratory
Creatinine (µmol/L) 86.0 ±27.27 5 .6 ±16.6. 1 9
Albumin (g/L) 45.3 ±2.34 4 .6 ±2.4. 3 9
Hemoglobin (g/L) 140.7 ±13.4 147.0 ±13.5. 1 8
Glucose (mmol/L) 6.4 ±1.05 .9 ±0.7. 1 5
BNP (pg/mL) 80.3 ±60.65 2 .9 ±43.9. 1 5
cTnI (µg/L) 0.010 ±0.009 0.008 ±0.007 .45
NT-proBNP (pg/mL) 580.4 ±712.9 289.9 ±215.8. 1 3
AOPP (µmol/L) 121.2 ±116.37 7 .0 ±28.5. 1 5
NGAL (ng/mL)
† 67.5 (60.0–115.5) 67.0 (60.0–90.8) .60
Cardiovascular parameters (at rest)
End diastolic volume (mL) 101.3 ±29.7 105.2 ±27.9. 7 0
End systolic volume (mL) 46.5 ±24.54 3 .8 ±19.1. 7 3
Ejection fraction (%) 56.7 ±10.66 1 .1 ±12.1. 2 7
†Data presented as median (IQR).
BNP: B-type natriuretic peptide, cTnI: cardiac troponin I, NT-proBNP: N-terminal-pro-B-type natriuretic peptide, AOPP: advanced oxidation protein
products, NGAL: neutrophil gelatinase-associated lipocalin.
lowerLVEFbothatrestandwithstresshaddetectableplasma
NGAL, thus suggesting similar association between chronic
heart failure and continuous kidney damage. The level of
NGAL has also been shown to correlate with severity and
progression of chronic kidney disease [31], which further
increases the prognostic importance of elevated NGAL.
Whether or not the damaged heart can be said to be
“signaling” the kidneys through mechanisms independent
of hemodynamic factors is the subject of ongoing study.
Future work may reveal if NGAL is a useful biomarker
in the evaluation of patients presenting with cardiorenal
syndromes.
While our experimental model demonstrated a measur-
able cardiorenal signal in the context of cardiac ischemia and
diminished LVEF with higher levels of BNPs, a secondary
aim was to identify evidence that the relationship between
cardiac ischemia and the kidneys was injurious to the
kidneys (type 1 or 2 cardiorenal syndrome). To this end,
we measured plasma NGAL as a marker of kidney injury.
Subjects with detectable levels of NGAL in the plasma
demonstrated greater incremental changes in natriuretic
peptides in response to stress, had more segmental perfusion
defects, higher end-diastolic and end-systolic volumes and
lower LVEF with stress, and had higher baseline levels of the
cardiac injury biomarker cTnI. Serum creatinine levels did
not diﬀer signiﬁcantly between the groups before or after
stress. While these observations are associations and do not
speak speciﬁcally to mechanism, one plausible conclusion
is that myocardial ischemia was contributing to a mild,
subclinical level of kidney injury. In addition, diminished
LVEF could be an injurious factor to renal tubular cells
causing continuous, prolonged kidney injury. An alternativeInternational Journal of Nephrology 5
Table 2: Changes in cardiac biomarkers, oxidative stress, and various cardiovascular imaging parameters compared between the high and
low ischemia (number of inducible myocardial perfusion defects) groups.
Study variable High inducible ischemia (n = 18) Low inducible ischemia (n = 16) P value
Laboratory
Creatinine (µmol/L)—at rest 86.0 ±27.27 5 .6 ±16.6 .19
Creatinine (µmol/L)—with stress 88.2 ±28.67 8 .5 ±18.0 .25
ΔCreatinine (µmol/L) 2.2 ±7.32 .9 ±8.0 .80
BNP (pg/mL)—at rest 80.3 ±60.65 2 .9 ±43.9 .15
BNP (pg/mL)—with stress 92.1 ±68.85 6 .8 ±40.3 .08
ΔBNP (pg/mL) 11.8 ±11.83 .8 ±7.2 .02
cTnI (µg/L)—at rest 0.010 ±0.009 0.008 ±0.007 .45
cTnI (µg/L)—with stress 0.016 ±0.014 0.008 ±0.007 .05
ΔcTnI (µg/L) 0.007 ±0.013 0.002 ±0.004 .16
NT-proBNP (pg/mL)—at rest 580.4 ±712.9 289.9 ±215.8 .13
NT-proBNP (pg/mL)—with stress 639.5 ±754.1 294.9 ±204.3 .08
ΔNT-proBNP (pg/mL) 59.1 ±84.95 .0 ±48.8 .03
AOPP (µmol/L)—at rest 121.2 ±116.37 7 .0 ±28.5 .15
AOPP (µmol/L)—with stress 95.0 ±102.26 5 .2 ±18.6 .26
ΔAOPP (µmol/L) −26.1 ±49.4 −11.8 ±26.2 .29
Cardiovascular parameters
Segmental perfusion defects—at rest 3.8 ±5.51 .8 ±3.5 .22
Segmental perfusion defects—with stress 10.7 ±7.12 .6 ±4.0 <.001
ΔSegmental perfusion defects 6.6 ±3.00 .8 ±0.8 <.001
End diastolic volume (mL)—at rest 101.3 ±29.7 105.2 ±27.9 .70
End diastolic volume (mL)—with stress 107.8 ±36.7 102.2 ±27.4 .63
ΔEnd diastolic volume (mL) 6.5 ±10.90 .1 ±8.8 .07
End systolic volume (mL)—at rest 46.5 ±24.54 3 .8 ±19.1 .73
End systolic volume (mL)—with stress 51.1 ±30.44 2 .3 ±19.7 .34
ΔEnd systolic volume (mL) 4.6 ±8.70 .4 ±8.6 .19
Ejection fraction (%)—at rest 56.7 ±10.66 1 .1 ±12.1 .27
Ejection fraction (%)—with stress 55.6 ±11.66 0 .6 ±11.0 .21
ΔEjection fraction (%) −1.1 ±3.9 −0.5 ±6.1 .74
Δ: delta (change from pre-stress to poststress test).
BNP: B-type natriuretic peptide, cTnI: cardiac troponin I, NT-proBNP: N-terminal-pro-B-type natriuretic peptide, AOPP: advanced oxidation protein
products, NGAL: neutrophil gelatinase-associated lipocalin.
explanation is that subjects with evidence of kidney injury
were predisposed to cardiac ischemia and/or decreased
systolic function (renocardiac syndrome).
There are a few limitations in our study that merit
discussion. Firstly, plasma NGAL was below the limits of
detection in many instances, and hence lacked sensitiv-
ity to detect subtle degrees of AKI following myocardial
stress and ischemia. Plasma and urinary NGAL have been
shown to be sensitive and speciﬁc indicators and predictive
biomarkers of acute kidney injury, in for instance, adult
intensive care unit patients with sepsis, children undergoing
cardiopulmonary bypass, adults with cardiac surgery, and
in patients with contrast-induced nephropathy [32]. NGAL
has performed especially well in relatively uncomplicated
patient populations with AKI, with excellent receiver-
operating characteristics [14, 32]. However, plasma NGAL
measurement may be inﬂuenced by several confounding
factors, such as systemic infections and inﬂammatory and
malignant processes [32], for which our study population
was not examined. It is also possible that in our study not
enoughtimehadelapsedfollowingstressforNGALtorise,as
moststudiesexaminingthekineticsofplasmaNGALseemto
indicatethatasigniﬁcantincreasetakesplacesmorethantwo
hours following the index event [15]. Future studies should
consider using a panel of plasma and urinary biomarkers for
AKIandfollowsubjectsforalongerperiodoftime.Secondly,
the possible inﬂuence of dipyridamole on biomarkers such
as NGAL and markers of oxidative stress should be taken
into consideration. As a substance with antioxidative and
antiapoptotic properties [33, 34], some of our results may
havesuﬀeredinterferencebythisagent.However,thelowand
high ischemia groups were well balanced in terms of their6 International Journal of Nephrology
Table 3: Results between groups based on existence of detectable plasma neutrophil gelatinase-associated lipocalin (NGAL).
Study variable Detectable NGAL (n = 23) No detectable NGAL (n = 11) P value
Laboratory
Creatinine (µmol/L)—at rest 84.0 ±25.27 5 .1 ±17.5. 2 4
Creatinine (µmol/L)—with stress 87.4 ±26.07 5 .9 ±19.4. 1 6
ΔCreatinine (µmol/L) 3.3 ±8.10 .8 ±6.1. 3 2
BNP (pg/mL)—at rest 73.8 ±57.65 3 .9 ±46.7. 2 9
BNP (pg/mL)—with stress 84.0 ±64.35 7 .5 ±44.0. 1 7
ΔBNP (pg/mL) 10.2 ±11.93 .5 ±4.8 .03
cTnI (µg/L)—at rest 0.010 ±0.009 0.006 ±0.003 .05
cTnI (µg/L)—with stress 0.013 ±0.010 0.012 ±0.016 .86
ΔcTnI (µg/L) 0.003 ±0.007 0.007 ±0.015 .39
NT-proBNP (pg/mL)—at rest 511.0 ±642.0 303.1 ±258.0. 1 9
NT-proBNP (pg/mL)—with stress 556.3 ±685.6 312.1 ±226.5. 1 3
ΔNT-proBNP (pg/mL) 45.4 ±83.29 .0 ±46.0. 1 1
AOPP (µmol/L)—at rest 105.7 ±102.08 9 .3 ±52.8. 5 4
AOPP (µmol/L)—with stress 85.8 ±91.17 1 .1 ±24.7. 4 8
ΔAOPP (µmol/L) −19.9 ±41.9 −18.2 ±38.6. 9 1
Cardiovascular parameters
Segmental perfusion defects—at rest 3.8 ±5.30 .9 ±2.1 .03
Segmental perfusion defects—with stress 8.2 ±8.04 .2 ±3.7. 0 6
ΔSegmental perfusion defects 4.1 ±3.83 .3 ±3.3. 5 1
End diastolic volume (mL)—at rest 108.4 ±25.99 0 .8 ±31.7. 1 4
End diastolic volume (mL)—with stress 112.8 ±32.59 0 .2 ±27.9 .05
ΔEnd diastolic volume (mL) 4.8 ±11.20 .8 ±8.0. 2 5
End systolic volume (mL)—at rest 49.9 ±21.53 4 .7 ±20.1. 0 7
End systolic volume (mL)—with stress 53.5 ±27.53 4 .4 ±18.0 .02
ΔEnd systolic volume (mL) 3.6 ±9.41 .1 ±7.4. 4 4
Ejection fraction (%)—at rest 55.8 ±10.66 5 .0 ±10.7 .03
Ejection fraction (%)—with stress 55.1 ±11.06 3 .8 ±10.3 .04
ΔEjection fraction (%) −0.7 ±5.1 −1.2 ±4.9. 7 8
Δ: delta (change from prestress to poststress test).
BNP: B-type natriuretic peptide, cTnI: cardiac troponin I, NT-proBNP: N-terminal-pro-B-type natriuretic peptide, AOPP: advanced oxidation protein
products, NGAL: neutrophil gelatinase-associated lipocalin.
exposure to dipyridamole, hence exposure should not have
led to spurious ﬁndings in one group over another. Like-
wise, the administration of aminophylline (a nonselective
adenosine receptor antagonist) as part of the stress imaging
protocol may have indirectly interfered with our results.
Adenosine can aﬀect renal function through its eﬀects on
renal blood ﬂow and tubuloglomerular feedback [35, 36],
however the likelihood of exposure to aminophylline was
similar in both high and low ischemia groups. Thirdly, the
observations made in this study do not clearly provide a
mechanism by which the ischemic heart is signaling the
kidneys (or vice versa). While the endocrine eﬀects of
natriuretic peptides as signaling agents are not in dispute,
one would not expect these to invoke kidney injury per se.
Having identiﬁed that there does seem to be a relationship
between the ischemic heart, and the heart with diminished
systolic function, with a biomarker of kidney injury, further
studies examining the role of cytokines, neurohormones,
mediators of apoptosis, and other injurious pathways are
planned. Additional limitations of our study are the rather
low number of patients, and the number of measurements
of plasma NGAL during the timecourse of the stress testing.
Using multiple measurements, increasing the sample size
and extending duration of posttest followup might have
presented with a more distinct and positive rise in NGAL
levels. Furthermore, the changes in the levels of cardiac
biomarkers, while rather low in a clinical sense, were
nonethelessstatisticallysigniﬁcant.Webelievethisrepresents
a weak yet discernible signal as evidence for heart-kidney
interactions.
To conclude, to our knowledge our study is novel
in demonstrating the association between the amount of
inducible myocardial ischemia with cardiorenal signaling
and biomarker of kidney injury. Furthermore, we present
the novel ﬁnding of the association between lower LVEF
and detectable NGAL in patients undergoing cardiac stressInternational Journal of Nephrology 7
testing. Our results display intriguing, yet at present only
suggestive insights into the signaling between the heart and
the kidneys. Further studies to elucidate mechanisms at
play in the complex bidirectional cardiorenal syndrome are
ongoing.
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